1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Preliminary study: Breast cancers can be well seen on 3T breast MRI with a half-dose of gadobutrol

      , , , ,
      Clinical Imaging
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dynamic contrast enhanced (DCE) breast MRI is highly sensitive for breast cancer and requires gadolinium-based contrast agents (GBCA)s, which have potential safety concerns. Test whether breast cancers imaged by 3T DCE breast MRI with 0.05mmol/kg of gadobutrol are detectable. Analysis of 3T DCE breast MRIs with half dose of gadobutrol from patients included in an IRB-approved and HIPPA-compliant prospective study of breast PET/MRI. Between 11/7/2014 and 3/2/2018, 41 consecutive women with biopsy-proven breast cancer that was at least 2cm, multi-focal or multi-centric, had axillary metastasis, or had skin involvement who gave informed consent were included. Two breast radiologists independently recorded lesion conspicuity on a 4-point scale (0=not seen, 1=questionably seen, 2=adequately seen, 3=certainly seen), and measured the lesion. Size was compared between radiologists and with size on available mammogram, ultrasound, MRI, and surgical pathology. Inter-reader agreement was assessed by kappa coefficient for conspicuity. Lesion size comparisons were assessed using the Spearman rank correlation. In 40 patients (ages 28.4 - 80.5, 51.9 years), there were 49 cancers. 10.1% of lesions were 1cm or less and 26.5% of lesions were 2cm or less. Each reader detected 49/49 cancers. Conspicuity scores ranged from 2-3, mean 2.9 /3 for both readers (p=0.47). Size on half-dose 3T DCE-MRI correlated with size on surgical pathology (r=0.6, p=0.03) while size on mammogram and ultrasound did not (r=0.25, p=0.46; r=0.25, p=0.42). All breast cancers in this cohort, as small as 0.4cm, were seen on 3T DCE breast MRI with 0.05mmol/kg dose of gadobutrol.

          Related collections

          Author and article information

          Journal
          Clinical Imaging
          Clinical Imaging
          Elsevier BV
          08997071
          November 2019
          November 2019
          : 58
          : 84-89
          Article
          10.1016/j.clinimag.2019.06.014
          6893111
          31279989
          9a1ff332-1a2a-4831-b3a8-f97515a68eb0
          © 2019

          https://www.elsevier.com/tdm/userlicense/1.0/

          History

          Comments

          Comment on this article